Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
Identifieur interne : 001093 ( PubMed/Corpus ); précédent : 001092; suivant : 001094Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
Auteurs : Anurodh Shankar Agrawal ; Xinrong Tao ; Abdullah Algaissi ; Tania Garron ; Krishna Narayanan ; Bi-Hung Peng ; Robert B. Couch ; Chien-Te K. TsengSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Coronavirus Infections (pathology), Coronavirus Infections (prevention & control), Hypersensitivity (pathology), Lung (pathology), Mice, Transgenic, Middle East Respiratory Syndrome Coronavirus (immunology), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, Inactivated, Viral Vaccines.
- chemical , adverse effects : Vaccines, Inactivated.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- immunology : Middle East Respiratory Syndrome Coronavirus, Vaccines, Inactivated, Viral Vaccines.
- pathology : Coronavirus Infections, Hypersensitivity, Lung.
- prevention & control : Coronavirus Infections.
- Animals, Mice, Transgenic.
Abstract
To determine if a hypersensitive-type lung pathology might occur when mice were given an inactivated MERS-CoV vaccine and challenged with infectious virus as was seen with SARS-CoV vaccines, we prepared and vaccinated mice with an inactivated MERS-CoV vaccine. Neutralizing antibody was induced by vaccine with and without adjuvant and lung virus was reduced in vaccinated mice after challenge. Lung mononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in the vaccine groups. Inactivated MERS-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS-CoV infection that is similar to that found with inactivated SARS-CoV vaccines from SARS-CoV infection.
DOI: 10.1080/21645515.2016.1177688
PubMed: 27269431
Links to Exploration step
pubmed:27269431Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.</title><author><name sortKey="Agrawal, Anurodh Shankar" sort="Agrawal, Anurodh Shankar" uniqKey="Agrawal A" first="Anurodh Shankar" last="Agrawal">Anurodh Shankar Agrawal</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tao, Xinrong" sort="Tao, Xinrong" uniqKey="Tao X" first="Xinrong" last="Tao">Xinrong Tao</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Algaissi, Abdullah" sort="Algaissi, Abdullah" uniqKey="Algaissi A" first="Abdullah" last="Algaissi">Abdullah Algaissi</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Narayanan, Krishna" sort="Narayanan, Krishna" uniqKey="Narayanan K" first="Krishna" last="Narayanan">Krishna Narayanan</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name><affiliation><nlm:affiliation>b Pathology, University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B" last="Couch">Robert B. Couch</name><affiliation><nlm:affiliation>c Internal Medicine, Division of Infectious Disease, University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27269431</idno><idno type="pmid">27269431</idno><idno type="doi">10.1080/21645515.2016.1177688</idno><idno type="wicri:Area/PubMed/Corpus">001093</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001093</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.</title><author><name sortKey="Agrawal, Anurodh Shankar" sort="Agrawal, Anurodh Shankar" uniqKey="Agrawal A" first="Anurodh Shankar" last="Agrawal">Anurodh Shankar Agrawal</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tao, Xinrong" sort="Tao, Xinrong" uniqKey="Tao X" first="Xinrong" last="Tao">Xinrong Tao</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Algaissi, Abdullah" sort="Algaissi, Abdullah" uniqKey="Algaissi A" first="Abdullah" last="Algaissi">Abdullah Algaissi</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Narayanan, Krishna" sort="Narayanan, Krishna" uniqKey="Narayanan K" first="Krishna" last="Narayanan">Krishna Narayanan</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name><affiliation><nlm:affiliation>b Pathology, University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B" last="Couch">Robert B. Couch</name><affiliation><nlm:affiliation>c Internal Medicine, Division of Infectious Disease, University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name><affiliation><nlm:affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (prevention & control)</term><term>Hypersensitivity (pathology)</term><term>Lung (pathology)</term><term>Mice, Transgenic</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Hypersensitivity</term><term>Lung</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Mice, Transgenic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine if a hypersensitive-type lung pathology might occur when mice were given an inactivated MERS-CoV vaccine and challenged with infectious virus as was seen with SARS-CoV vaccines, we prepared and vaccinated mice with an inactivated MERS-CoV vaccine. Neutralizing antibody was induced by vaccine with and without adjuvant and lung virus was reduced in vaccinated mice after challenge. Lung mononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in the vaccine groups. Inactivated MERS-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS-CoV infection that is similar to that found with inactivated SARS-CoV vaccines from SARS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27269431</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.</ArticleTitle><Pagination><MedlinePgn>2351-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1177688</ELocationID><Abstract><AbstractText>To determine if a hypersensitive-type lung pathology might occur when mice were given an inactivated MERS-CoV vaccine and challenged with infectious virus as was seen with SARS-CoV vaccines, we prepared and vaccinated mice with an inactivated MERS-CoV vaccine. Neutralizing antibody was induced by vaccine with and without adjuvant and lung virus was reduced in vaccinated mice after challenge. Lung mononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in the vaccine groups. Inactivated MERS-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS-CoV infection that is similar to that found with inactivated SARS-CoV vaccines from SARS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Anurodh Shankar</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Xinrong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Algaissi</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>e Department of Medical Laboratories Technology , College of Applied Medical Sciences, Jazan University , Jazan , Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garron</LastName><ForeName>Tania</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayanan</LastName><ForeName>Krishna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Bi-Hung</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>b Pathology, University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couch</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>c Internal Medicine, Division of Infectious Disease, University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chien-Te K</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>a Departments of Microbiology and Immunology , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>d Center for Biodefense and Emerging Infectious Disease, University of Texas Medical Branch , Galveston , TX , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI060549</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI113206</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC7 AI094660</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006967" MajorTopicYN="N">Hypersensitivity</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">coronavirus; Eosinophils; immunopathology; Middle East Respiratory Syndrome; vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27269431</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1177688</ArticleId><ArticleId IdType="pmc">PMC5027702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):422-34</Citation><ArticleIdList><ArticleId IdType="pubmed">4305198</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):405-21</Citation><ArticleIdList><ArticleId IdType="pubmed">4305197</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Mar;89(6):2995-3007</Citation><ArticleIdList><ArticleId IdType="pubmed">25520500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1994 Nov;94(5):1953-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7962541</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Apr;88(7):3902-10</Citation><ArticleIdList><ArticleId IdType="pubmed">24453361</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Nov 1;181(9):6337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18941225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 May;81(10):5423-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17344286</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2015 May;15(5):271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25882242</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2009 Jul;7(7):749-755.e11</Citation><ArticleIdList><ArticleId IdType="pubmed">19345285</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Mar 19;140(6):777-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20303868</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Apr;89(7):3659-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25589660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Aug;88(15):8597-614</Citation><ArticleIdList><ArticleId IdType="pubmed">24850731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Oct 07;90(1):57-67</Citation><ArticleIdList><ArticleId IdType="pubmed">26446606</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e35421</Citation><ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nanomedicine. 2015 Jul 14;10:4491-505</Citation><ArticleIdList><ArticleId IdType="pubmed">26203246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Dec;85(23):12201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2004 Aug;4(8):583-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15286725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2003 Feb 15;170(4):2037-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12574374</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001093 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001093 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27269431
|texte= Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27269431" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |